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Available online 31 August 2011The digestive-enzyme secreting, gastric epithelial chief (zymogenic) cell is remarkable and under-
appreciated. Here, we discuss how all available evidence suggests that mature chief cells in the
adult, mammalian stomach are postmitotic, slowly turning over cells that arise via a relatively
long-lived progenitor, the mucous neck cell, The differentiation of chief cells from neck cells
does not involve cell division, and the neck cell has its own distinct pattern of gene expression
and putative physiological function. Thus, the ontogeny of the normal chief cell lineage exem-
plifies transdifferentiation. Furthermore, under pathophysiogical loss of acid-secreting parietal
cell, the chief cell lineage can itself trasndifferentiate into a mucous cell metaplasia designated
Spasmolytic Polypeptide Expressing Metaplasia (SPEM). Especially in the presence of inflamma-
tion, this metaplastic lineage can regain proliferative capacity and, in humans may also further dif-
ferentiate into intestinal metaplasia. The results indicate that gastric fundic lineages display
remarkable plasticity in both physiological ontogeny and pathophysiological pre-neoplastic meta-
plasia.
© 2011 Elsevier Inc. All rights reserved.Keywords:
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Normal chief cell location and function
The gastric epithelium is organized as a series of roughly funnel-
shaped invaginations from the gastric lumen known as gastric
units. In the glandular portion of the stomach (known in most spe-
cies as the corpus or body) each gastric unit is broadest where it
adjoins the gastric lumen proper. This broad pit region is lined
by simple columnar, mucus-secreting epithelium. Below the pit
zone, the gastric unit narrows into one or multiple glandular
branches. In mammals, proliferative activity and the presumptive
stem cell are located where the pit narrows into each gland in a
small region known as the isthmus [1,2]. The glands secrete both
digestive enzymes and acid, a function that can be performed by
a single oxyntico-peptic cell in birds [3,4], whereas in mammals,
these functions are divided into two autonomous lineages: acid-
secreting parietal cells and digestive-enzyme (zymogenic) pro-
ducing chief cells. Even in mammals, parietal and chief cells likely
develop from a common progenitor [5,6]. Chief cells occupy most
of the base of a gastric gland, the upper ones organized as simple
cuboido-columnar cells, the lower ones outpouching into anFig. 1 – The cellular lineage ontogeny of normal gastric chief cells. A
cells. B. Transcription factor cascade responsible for maturation ofacinar configuration at the very base [7]. Parietal cells can occur
throughout the gastric unit, but the vast majority are located in
the neck of the gland, between the isthmus and the base [8,9].
Normal chief cell maturation requires XBP1 and MIST1
The chief cell is a large cell with an extensive network of lamellar
rough endoplasmic reticulum (rER), concentrated around the ba-
sally oriented nucleus, and numerous, large, apical exocrine secre-
tory granules filled with digestive enzymes. Recent studies have
identified the transcription factors regulating this specialized cel-
lular architecture. Conditional deletion of X-Box Binding Protein
1, XBP1, in mice leads to small chief cells with only scattered,
scant rER [10], consistent with the known role of XBP1 in inducing
cellular rER formation. XBP1 directly induces the basic Helix-Loop-
Helix (bHLH) transcription factor MIST1 (Fig. 1). MIST1
(BHLHA15) is required for the basal localization of the nucleus
and the maintenance of substantial apical cytoplasm filled with
abundant, large vesicles [11]. Thus, chief cell structure is seeming-
ly completely dependent on an XBP1 to MIST1 sequence, wherein
XBP1 directly induces the extensive rER network (for translation
of all the digestive enzymes), and MIST1 in turn regulates the. Scheme for the origin of chief cell lineages frommucous neck
normal chief cells.
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secretory machinery to store and release them in a regulated
fashion.
Chief cells normally arise by transdifferentiation
Normal chief cells do not derive directly from gastric epithelial
progenitor cell lineages, but rather through an intermediate cell
type, characterized by abundant mucinous vesicles in the neck of
the gland (Fig. 1). These mucous neck cells do differentiate direct-
ly from the normal gland stem cell via recognizable precursor
(“pre-neck”) forms, thereafter migrating basally in amongst parie-
tal cells in the neck until they rapidly transition into chief cells as
they reach the base [12]. Mucous neck cells differ from chief cells
in that they have their own distinct pattern of gene expression
(e.g., Gkn3, Tff2,Muc6), a distinct morphology (they have thin pro-
jections to the basement membrane and broad apices facing the
gastric unit lumen), and presumably thus a separate physiological
function (to secrete mucins). However, there is little if any pub-
lished evidence that demonstrates what the purpose of their
mucus secretion, if it occurs, is. Nucleotide analog (3H-thymidine,
Bromodeoxyruidine) uptake experiments indicate that neck cells
survive for 9–16 days [11,13]. Therefore, mucous neck cells appear
to represent a separate lineage and, if they are progenitors for
chief cells, this differentiation pattern of a long-lived cell with
one phenotype from a relatively long-lived cell type with its own
gene expression and morphology pattern is quite remarkable
and may involve a number of heretofore unappreciated cellular
differentiation mechanisms [12].
Because the process of mucous neck cell to chief cell differenti-
ation does not require cell division, it represents an example of
transdifferentiation. The evidence for this transdifferentiation
from mucous neck to chief cell is extensive. First, as mentioned,
nucleotide analog tracing shows that cells with chief and pre-
chief cell morphology or marker expression, rarely, if ever, di-
vide. Rather, it takes several days following nucleotide analog
administration before the analogs are found in chief cells, indi-
cating that chief cells arise from a precursor or intermediate
[7,11]. In such studies, the nuclear-analog-positive cells that
first appear are those with features hybrid between the chief
and neck cells, and those hybrid cells are found at the transition
between the neck and the base. Second, in almost every gland,
there are cells at the transition between the neck and the base
that co-express neck and chief cell markers [8,11] and, on elec-
tron microscopy and immune electron microscopy, have secre-
tory granules containing both mucin and digestive enzymes
[11,13,14]. Third, the first mature chief cells arise late in devel-
opment, and a full complement is achieved only around the
time of weaning in rats and mice. Immature glands are populat-
ed instead by cells with mixed neck-chief cell characteristics
that gradually resolve into distinct neck and chief cell popula-
tions [15]. Similarly, injury [16] and transplantation [17] studies,
not to mention studies of metaplasia that will be discussed later
in this review, all indicate that cells with mucous neck cell and
chief cell phenotypes are inter-convertible and hence simply
two different manifestations or stages of the same lineage.
Fourth, the transcription factor MIST1 is expressed only in
chief cells and in about half of the cells with hybrid neck-chief
cell characteristics in the transition between the neck and base
zones. In Mist1−/− mice, there are significantly more cells ofneck-chief hybrid phenotype, suggesting that loss of MIST1
causes a delay in the normal transition [11]. Chief cells arising
after XBP1—which induces MIST1 and is thus further upstream
in chief cell differentiation—is conditionally deleted, all show
hybrid neck-chief cell characteristics.
In summary, nucleotide analog, morphological, developmental,
pathophysiological, and molecular data support the remarkable
conclusion that the chief cell lineage exhibits a dramatic pheno-
typic transition as part of its normal homeostasis. Furthermore,
this differentiation pattern appears remarkably malleable, which
we will examine further in subsequent sections.Loss of parietal cells leads to transdifferentiation of
mature chief cells into SPEM
While controversy exists as to the sequence and connection of
mucosal lineage changes associated with increased risk for gastric
cancer, there is a general agreement that the loss of acid secreting
parietal cells, also known as oxyntic atrophy, is a prerequisite for
induction of metaplasia [18]. A number of investigators over the
past decade have therefore sought to identify aspects of the cas-
cade of lineage changes associated with parietal cell loss. A semi-
nal advance was the characterization of the Helicobacter felis
infection model in C57BL/6 mice by Fox and Wang [19,20].
C57BL/6 mice infected with H. felis demonstrate progressive loss of
parietal cells over 4–6 months of infection and the gastric mucosa
is replaced with a mucous cell metaplasia in the gastric fundus
with sparing of the gastric antrum. These metaplastic mucous cells
express TFF2, also known as spasmolytic polypeptide, leading to the
designation of this lineage as spasmolytic polypeptide-expressing
metaplasia or SPEM [20,21]. SPEM was also identified in the mucosa
surrounding intestinal type gastric cancers in humans [22]. This mu-
cous cell lineage, which also expressesMUC6, ismorphologically sim-
ilar to the deep gland cells of the antrum or the Brunner's gland cells.
Importantly, C57BL/6mice infectedwithH. felis for over 9–12 months
showed progression of the metaplasia to gastritis cystica profunda,
with dysplastic glands penetrating into the submucosa and muscu-
laris layers of the stomach wall [19,20]. These results indicated that,
in the face of chronic parietal cell loss and inflammation, metaplastic
glands could progress towards dysplasia.
In addition to this chronic model, methods for induction of
acute oxyntic atrophy became available in 2000. Treatment of
mice and rats with the neutrophil elastase inhibitor DMP-777
caused rapid loss of parietal cells from the gastric mucosa over
3–4 days of daily dosing [23,24]. This drug causes direct parietal
cell death due to its action as a parietal cell-specific apical mem-
brane protonophore, which allows entry of acid into parietal
cells and specific cell toxicity. The effects of DMP-777 are amelio-
rated by pretreatment with omeprazole [25]. Following initial pari-
etal cell loss, after 7–10 days of daily treatment, SPEM emerges
from the bases of glands coincidentwith the appearance of scattered
proliferative cells at the bases of fundic glands [23,24]. No significant
changes are observed in the antrum. Importantly, while metaplastic
lineages are maintained in mice and rats dosed for over a year with
DMP-777, no evidence of gastritis cystica profunda or dysplasia de-
velops, suggesting that inflammation is required for progression of
metaplasia to neoplasia [23].
More recently we have examined the effects of a variant of
DMP-777, designated L-635, which still possess strong parietal
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neutrophil elastase [26]. Like DMP-777, treatment of mice with
L-635 leads to a rapid loss of parietal cells within 2–3 days of
daily dosing. However, unlike DMP-777, the loss of parietal cells
is accompanied by an exuberant inflammatory response. In L-
635 treated mice, we observed development of prominent SPEM
after only 3 days of treatment and the SPEM was highly prolifera-
tive. Indeed, the SPEM elicited by only 3 daily doses of L-635 in-
duced a phenotype remarkably similar to that observed in mice
infected with H. felis for 6–9 months [26]. Unfortunately, it re-
mains unclear whether chronic dosing with L-635 would lead to
dysplastic changes, as seen with H. felis, because of the very limit-
ed availability of the compound.
While all of these studies clearly linked the loss of parietal cells
to the induction of SPEM, the question remained as to the origin of
this metaplastic mucous cell lineage. Previous biases have sug-
gested that metaplasias and dysplasias would arise from profes-
sional resident progenitor cells that alter their program of
differentiation. However, a number of observations called into
question the derivation of SPEM from normal progenitor cells,
which are located above the neck of the gland, in the isthmus re-
gion. First, treatment with DMP-777 led to induction of SPEM ini-
tiated from the bottoms of gastric glands rather than from the
isthmus [24]. Second, after 10–14 days of DMP-777 treatment,
one can observe two groups of BrdU positive cells, one in the isth-
mus below foveolar hyperplastic surface mucous cells and one at
the bases of fundic glands [23,24]. These results suggested that a
second population of proliferative cells was induced following
loss of parietal cells. While no Ki-67 staining was observed in nor-
mal chief cells, after induction of SPEM with acute parietal cell
loss, Ki-67-staining were observed in the bases of fundic glands.
Third, in the context of acute oxyntic atrophy, we observed cells
at the bases of fundic glands with immunostaining for both TFF2
and intrinsic factor in separate secretory granules [24]. Electron
microscopy analysis of these cells demonstrated the presence of
zymogen granules and vesicles with mucous granule phenotype
as well as other small clear vesicles. These findings contrast with
those for pre-zymogenic cells, where hybrid granules containing
both zymogens and mucins are observed [11]. Fourth, in the
gastrin-deficientmousemodel, where induction of SPEM ismarkedly
accelerated in response to acute oxyntic atrophy, in mice treated for
1–2 days with DMP-777, we observed cells that were dually positive
for both MIST1 and TFF2 [27]. All of these studies led to an initial im-
pression that SPEM was evolving from MIST1-positive chief cells.
To evaluate this novel hypothesis for the origin of metaplasia
from a mature post-mitotic lineage, we pursued a lineage map-
ping approach utilizing Mist1-CreERT2;Rosa26R(LacZ) mice [26].
Treatment of these mice with tamoxifen caused induction of Cre
recombinase only in mature chief cells and resulted in the marking
of these cells with the expression of bacterial β-galactosidase. After
resting the mice for 10 days without treatment, the mice were
then subjected to one of the three models of oxyntic atrophy and
SPEM induction with acute treatment with DMP-777 for 14 days,
acute treatment with L-635 for 3 days or infection with H. felis for
6 months. Remarkably, all three models demonstrated derivation
of SPEM from mature chief cells marked with β-galactosidase ex-
pression [26]. However, themost dramatic lineagemappingwas ob-
served in the acute and chronic models of oxyntic atrophy
associated with inflammation (L-635 treatment and H. felis infec-
tion, respectively), where essentially the entire SPEM lineage wasderived from chief cells. These results indicate that the loss of parie-
tal cells can induce transdifferentiation of chief cells into SPEM and
that this metaplasia can undergo expansion under the influence of
acute or chronic inflammatory infiltrates.The relationship of SPEM to intestinal metaplasia
In humans, both SPEM and intestinal metaplasia are observed in
the stomachs of gastric cancer patients. While SPEM possesses the
characteristics of antral metaplasia, including expression of TFF2
andMUC6, intestinal metaplasia demonstrates clear lineage charac-
teristics of the duodenum of intestines, with expression of TFF3 and
MUC2 [28]. Nevertheless, while both metaplasias do exist in
humans, it has been difficult to discern the relationship of these
metaplasias because Helicobacter infection in mice does not result
in intestinal metaplasia. Nevertheless, H. pylori infection of other
species, such as Mongolian gerbils, does induce intestinal metapla-
sia and eventually dysplasia and cancer [29–33]. A recent study by
Nomura and colleagues addressed the relationship of SPEM and in-
testinal metaplasia through a detailed examination of the histo-
pathological changes associated with H. pylori infection in the
Mongolian gerbil [33]. After 3 weeks of H. pylori infection, gerbils
developed SPEM in the presence of parietal cell loss. While exten-
sion and expansion of SPEM was observed over the following
weeks, after 24 weeks intestinal metaplasia arose from sites sur-
rounded by mucosa with pre-existing SPEM. In single gland units
these investigators observed goblet cell containing intestinal meta-
plasia (as marked by expression of MUC2) luminal to SPEM line-
ages expressing TFF2 [33]. In these glands, cells at the transition
between SPEM and intestinal metaplasia expressed markers of
both SPEM and intestinal metaplasia (e.g. MUC2 and TFF2).
While no intestinal metaplasia has been observed in Helicobac-
ter sp.-infected mice, older amphiregulin mutant mice develop in-
testinal metaplasia and dysplasia in the setting of pre-existing
SPEM [34]. As with the gerbils, SPEM developed spontaneously
in amphiregulin-deficient mice after 9 months of age. In addition,
MUC2-expressing intestinal metaplasia developed within glands
also expressing SPEMmarkers after 1 year of age. As in the gerbils,
hybrid cells expressing both MUC2 and TFF2 were observed in
transition zones within dysplastic regions [34]. These results sup-
ported the concept that SPEM is the first metaplasia arising after
induced oxyntic atrophy, and then, with subsequent on-going
chronic inflammation, intestinal metaplasia arises as a second
metaplastic transition (Fig. 2).
A similar relationship between SPEM and intestinal metapla-
sia likely exists in humans [35,36]. In the stomach, we have ob-
served the presence of compound glands that demonstrate
SPEM at their bases and intestinal metaplasia towards the sur-
face. These studies support the concept that intestinal metapla-
sia evolves directly from pre-existing SPEM. However, another
interpretation is also possible. It may be that loss of parietal
cells is necessary but not sufficient for intestinal metaplasia,
whereas loss of parietal cells is sufficient for SPEM. Thus, SPEM
will always be present when there is new oxyntic atrophy and
will also be present in the vicinity of any newly induced intesti-
nal metaplasia. Recent evidence using MIST1, TFF2, and CDX2 as
markers suggested SPEM and intestinal metaplasia in humans
might also arise independently from transdifferentiating chief
cells during parietal cell loss [37].
Fig. 2 – Current model for the origin and progression of gastric metaplasias. The preponderance of data indicates that chief cell
transdifferentiation into SPEM is triggered by loss of parietal cells in the fundic mucosa. In the face of inflammation, SPEM can
expand into a proliferative metaplasia. With continued chronic inflammation, intestinal metaplasia evolves in the setting of pre-
existing SPEM and can come to dominate the entirety of the glands.
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similar to the evolution ofmucous cellmetaplastic lineages reported
byWright and colleagues in the context of mucosal restitution in in-
flammatory bowel disease [38]. This induction of a secondmetaplas-
tic transition may reflect the severity and chronicity of mucosal
damage as well as indicate an increased risk for neoplastic transfor-
mation. Interestingly, recent studies by McDonald and colleagues
have suggested that intestinal metaplasia glands are clonal [39].
However, a comparison of mutations in intestinal metaplasia glands
and adjacent dysplasia identified mapping of mutations in less than
10% of samples. It therefore remains uncertain whether SPEM also
gives rise to dysplastic lineages or whether the presence of mixed
metaplasia is indicative of an unstable genetic milieu that gives
rise to neoplastic transformation.Summary
The gastric fundic mucosa demonstrates processes of transdifferen-
tiation in both physiological lineage derivation aswell as in the path-
ophysiology of mucous cell metaplasia. In the normal adult fundic
mucosa, mucous neck cells transdifferentiate into chief cells as
they migrate towards the bases of fundic glands. This mucous cell
to zymogen cell transition occurs without any intervening cell divi-
sion to produce a chief cell population that by all standard criteria is
postmitotic. Nevertheless, in the presence of significant parietal cell
loss, chief cells can go through a process for zymogen cell tomucous
cell transdifferentiation that leads to the formation of mucous cell
metaplasia. This pathophysiological transdifferentiation, especially
in the presence of inflammatory influences can lead to recrudes-
cence of proliferative capacity. While previous studies have indicat-
ed that transdifferentiation of chief cells into SPEM is associatedwith upregulation of a number of proteins associated with DNA un-
winding (e.g. MCMproteins) [27]. However, overall, the cellular and
molecular pathways used to reshape lineage secretory profiles, both
physiologically and pathophysiologically, largely remain a mystery
investigated by only a handful of studies to date. If we are to under-
stand the process of gastric carcinogenesis, we must understand
both how SPEM is induced by parietal cell loss and the relationship
of SPEM to intestinal metaplasia and ultimately dysplasia. Future
studies should give new insights into the cellular mechanisms re-
sponsible for the remarkable plasticity of gastric fundic lineages.Acknowledgments
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